R112: Phase II data

In a placebo-controlled Phase II trial in 319 patients, R112 reduced the Global Nasal Allergy Symptom Score by 7 points (38%) vs. 5.4 points (29%) for placebo at day 1 (p=0.0005). The results also wer...